

#### Anti-LAG3 / CD223 Reference Antibody (miptenalimab) Recombinant Antibody Catalog # APR10646

#### Specification

## Anti-LAG3 / CD223 Reference Antibody (miptenalimab) - Product Information

Application Primary Accession Reactivity Clonality Isotype Calculated MW FC, Kinetics, Animal Model <u>P18627</u> Human Monoclonal IgG4SP 145.04 KDa

### Anti-LAG3 / CD223 Reference Antibody (miptenalimab) - Additional Information

Target/Specificity LAG3 / CD223

**Endotoxin** < 0.001EU/ μg,determined by LAL method.

Conjugation Unconjugated

Expression system CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

#### Anti-LAG3 / CD223 Reference Antibody (miptenalimab) - Protein Information

Name LAG3 (HGNC:6476)

Synonyms FDC

Function

Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:<a href="http://www.uniprot.org/citations/20421648" target="\_blank">20421648</a>, PubMed:<a href="http://www.uniprot.org/citations/7805750" target="\_blank">7805750</a>, PubMed:<a href="http://www.uniprot.org/citations/7805750" target="\_blank">7805750</a>, PubMed:<a href="http://www.uniprot.org/citations/8647185" target="\_blank">8647185</a>). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and



CD4(+) T-cells (PubMed:<a href="http://www.uniprot.org/citations/20421648" target=" blank">20421648</a>, PubMed:<a href="http://www.uniprot.org/citations/7805750"

target= \_blank >20421048</a>, PubMed:<a href="http://www.uniprot.org/citations/7805750 target="\_blank">7805750</a>, PubMed:<a href="http://www.uniprot.org/citations/8647185" target="\_blank">8647185</a>). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:<a href="http://www.uniprot.org/citations/8647185" target=" blank">8647185</a>).

#### **Cellular Location** [Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein


**Tissue Location** Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.

# Anti-LAG3 / CD223 Reference Antibody (miptenalimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

### Anti-LAG3 / CD223 Reference Antibody (miptenalimab) - Images



Anti-LAG3 / CD223 Reference Antibody (miptenalimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%





The purity of Anti-LAG3 / CD223 Reference Antibody (miptenalimab)is more than 95% ,determined by SEC-HPLC.